Market Place
Sourcing Support
Newron Licenses Evenamide To EA Pharma For Asian Territories
13 Dec 2024 //
BUSINESSWIRE
Leqembi® approved in Mexico
04 Dec 2024 //
PR NEWSWIRE
Leqembi (Lecanemab) Launched in South Korea for Alzheimer`s Disease
27 Nov 2024 //
PR NEWSWIRE
Leqembi® launched in South Korea
27 Nov 2024 //
PR NEWSWIRE
Eisai ends lorcaserin development in Dravet syndrome
18 Nov 2024 //
FIERCE PHARMA
EU backs Eisai-Biogen Alzheimer`s drug after initial rejection
16 Nov 2024 //
REUTERS
EU regulators endorse meds from BMS, J&J, Eisai and more
15 Nov 2024 //
FIERCE PHARMA
Eisai Upgrades Leqembi Sales Forecast To JPY 42.5 bn For Fis 2024
07 Nov 2024 //
PR NEWSWIRE
Eisai Completes BLA Submission for Leqembi® Subcutaneous Dosing
31 Oct 2024 //
PR NEWSWIRE
Eisai Presents Lecanemab Long-Term Data at CTAD Conference
30 Oct 2024 //
GLOBENEWSWIRE
Eisai Long-Term Lecanemab Data at 17th CTAD Conference
30 Oct 2024 //
PR NEWSWIRE
Eisai Presents Data on Inhibiting Tau Propagation with E2814
30 Oct 2024 //
PR NEWSWIRE
Eisai To Present Updated Lecanemab Data And Blood Biomarker At CTAD
23 Oct 2024 //
PR NEWSWIRE
Eisai To Request Reconsideration Of Lecanemab In Australia
16 Oct 2024 //
PR NEWSWIRE
Suboptimal Leqembi vials could create millions in waste
15 Oct 2024 //
FIERCE PHARMA
Thailand approves therapeutic medicine for gout and hyperuricemia
08 Oct 2024 //
BIOSPECTRUM
FDA Issues Form 483 to Eisai
24 Sep 2024 //
FDA
SEED Therapeutics Appoints Dr. Yoshiharu Mizui To Board Of Directors
12 Sep 2024 //
GLOBENEWSWIRE
Eisai To Present E7386 At ESMO Annual Meeting
08 Sep 2024 //
PR NEWSWIRE
Eisai Presents New Data at ESMO Congress, Including LEAP-012 Interim Results
04 Sep 2024 //
PR NEWSWIRE
IGC Pharma Advances IGC-AD1 Toward Trials for Alzheimer`s Anti-Amyloid Treatment
04 Sep 2024 //
BUSINESSWIRE
New Alzheimer`s drug deemed too costly for UK`s state-run health service
22 Aug 2024 //
REUTERS
BioArctic Comments On Lecanemab Approval Rumors In Britain
22 Aug 2024 //
PR NEWSWIRE
Eisai plants molecular glue SEED with $1.5B biobucks deal in neuro, oncology
07 Aug 2024 //
FIERCE BIOTECH
Biogen lifts profit forecast, signals progress in turnaround effort
01 Aug 2024 //
REUTERS
Eisai, Biogen Show Leqembi`s Added Benefits Over Time
31 Jul 2024 //
FIERCE PHARMA
Benefit of Eisai and Biogen`s Alzheimer`s drug increases over time, studies suggest
31 Jul 2024 //
REUTERS
Alzheimer`s drug from Eisai and Biogen rejected in Europe
27 Jul 2024 //
REUTERS
Eisai and EcoNaviSta to build dementia ecosystem in Japan
25 Jul 2024 //
BIOSPECTRUM ASIA
Eisai First Big Buyer For Medidata`s New Clinical Trial Management Platform
25 Jul 2024 //
FIERCE BIOTECH
Eisai Partners With Sato Pharma For Fosravuconazole In Asia And Oceania
22 Jul 2024 //
BIOSPECTRUM ASIA
Lilly Aims For Alzheimer`s Market Leadership Following Kisunla Approval
11 Jul 2024 //
FIERCE PHARMA
Eisai to trial orexin-2 receptor agonist in narcolepsy patients
08 Jul 2024 //
PR NEWSWIRE
Japan`s Eisai terminates ADC manufacturing pact with BMS
03 Jul 2024 //
BIOSPECTRUM ASIA
Japan`s Eisai developing dementia drug for US market, Nikkei reports
01 Jul 2024 //
REUTERS
Ensho emerges with inflammatory disease portfolio from Eisai`s EA Pharma
28 Jun 2024 //
FIERCE BIOTECH
New Efficacy Data for Non-Clear Cell RCC a From KEYNOTE-B61 Added to LENVIMA
27 Jun 2024 //
PR NEWSWIRE
New Analysis From Phase 3 REFLECT Trial On LENVIMA At ESMO GI 2024
27 Jun 2024 //
PR NEWSWIRE
Lilly Alzheimer`s drug gets unanimous backing from FDA advisory panel
11 Jun 2024 //
REUTERS
FDA accepts Eisai`s monthly dosing application for Leqembi
11 Jun 2024 //
FIERCE PHARMA
FDA Accepts Eisai’s Filing of LEQEMBI sBLA for IV for Early Alzheimer’s Disease
07 Jun 2024 //
GLOBENEWSWIRE
Lilly tipped to beat Eisai, Biogen, win $13B Alzheimer`s fight
07 Jun 2024 //
FIERCE PHARMA
US FDA staff raise no major concerns about Eli Lilly Alzheimer`s drug
07 Jun 2024 //
REUTERS
Eisai`s LEQEMBI receives approval in South Korea for treatment of AD
28 May 2024 //
BIOSPECTRUM ASIA
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
23 May 2024 //
PR NEWSWIRE
Metoject subcutaneous inj pen launches in Japan rheumatic arthritis treatment
22 May 2024 //
BIOSPECTRUM ASIA
Eisai predicts sharp Leqembi sales increase this year
16 May 2024 //
FIERCE PHARMA
Eisai Projects Leqembi Revenue JPY 56.5B For FY2024
15 May 2024 //
PR NEWSWIRE
Eisai Initiates Leqembi Rolling BLA For Subcutaneous Maintenance Dosing
14 May 2024 //
PR NEWSWIRE
Eisai Initiates Leqembi Rolling BLA For Early Alzheimer`s Subcutaneous Dosing
14 May 2024 //
GLOBENEWSWIRE
Eisai starts rolling submission for inj. version of Alzheimer`s drug US FDA
14 May 2024 //
REUTERS
GHIT Fund invests Y1.54bn in malaria and NTD drug projects
09 May 2024 //
PHARMACEUTICAL TECHNOLOGY
USD 10.8 Million Investment for Malaria and NTDs Drug Development
08 May 2024 //
PR NEWSWIRE
US FDA panel to discuss Eli Lilly Alzheimer`s drug on June 10
08 May 2024 //
REUTERS
People with two copies of a risk gene have genetic form of Alzheimer`s, scientists say
07 May 2024 //
REUTERS
Biogen plots 30% Leqembi field force bump, omnichannel campaigns
25 Apr 2024 //
FIERCE PHARMA
Biogen cost cuts drive profit beat, as Alzheimer`s drug off to slow start
25 Apr 2024 //
REUTERS
Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024
24 Apr 2024 //
PR NEWSWIRE
Alzheimer`s drug adoption in US slowed by doctors` skepticism
23 Apr 2024 //
REUTERS
BioArctic, Eisai Sign BAN2802 Research Evaluation Agreement
20 Apr 2024 //
PR NEWSWIRE
